{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:30Z","timestamp":1790753790951,"version":"4.1.0"},"reference-count":180,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.03127","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T23:37:10Z","timestamp":1581032230000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":98,"title":["Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhongji","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengji","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Collaborators","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","article-title":"Natural history of chronic hepatitis B REVEALed","volume":"26","author":"Chen","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5114\/ceh.2017.67626","article-title":"Recommendations for the treatment of hepatitis B in 2017","volume":"3","author":"Flisiak","year":"2017","journal-title":"Clin Exp Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/hep.29213","article-title":"A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/apt.14629","article-title":"Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance","volume":"47","author":"Qiu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2016.05.043","article-title":"Aiming for cure in HBV and HDV infection","volume":"65","author":"Petersen","year":"2016","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e01032","DOI":"10.1128\/JVI.01032-19","article-title":"Revisiting hepatitis B virus: challenges of curative therapies","volume":"93","author":"Hu","year":"2019","journal-title":"J Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nm.3251","article-title":"Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells","volume":"19","author":"Rehermann","year":"2013","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S765","DOI":"10.1093\/infdis\/jix356","article-title":"Immunopathogenesis of hepatitis B virus","volume":"216","author":"Tseng","year":"2017","journal-title":"J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.virusres.2017.12.007","article-title":"Current concepts on immunopathogenesis of hepatitis B virus infection","volume":"245","author":"Peeridogaheh","year":"2018","journal-title":"Virus Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.gastro.2018.08.061","article-title":"Insights from antiviral therapy into immune responses to hepatitis B and C virus infection","volume":"156","author":"Rehermann","year":"2019","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.celrep.2016.06.078","article-title":"Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host","volume":"16","author":"Schurich","year":"2016","journal-title":"Cell Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fimmu.2018.00472","article-title":"Hyper-expression of PD-1 is associated with the levels of exhausted and dysfunctional phenotypes of circulating CD161(++)TCR iValpha7","volume":"9","author":"Yong","year":"2018","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1053\/j.gastro.2012.08.046","article-title":"Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection","volume":"143","author":"Martinet","year":"2012","journal-title":"Gastroenterology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/j.1365-2893.2011.01496.x","article-title":"Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells","volume":"19","author":"Shi","year":"2012","journal-title":"J Viral Hepat"},{"key":"B22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fimmu.2013.00057","article-title":"NK cells: a double-edged sword in chronic hepatitis B virus infection","volume":"4","author":"Maini","year":"2013","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fimmu.2019.00112","article-title":"Circulating and hepatic BDCA1+, BDCA2+, and BDCA3+ dendritic cells are differentially subverted in patients with chronic HBV infection","volume":"10","author":"Ouaguia","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection","volume":"53","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nri.2016.69","article-title":"Immune responses and immunopathology in acute and chronic viral hepatitis","volume":"16","author":"Shin","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/hep.21482","article-title":"Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein","volume":"45","author":"Visvanathan","year":"2007","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clim.2008.04.006","article-title":"Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients","volume":"128","author":"Chen","year":"2008","journal-title":"Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.antiviral.2015.03.004","article-title":"Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy","volume":"118","author":"Huang","year":"2015","journal-title":"Antiviral Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00430-014-0370-1","article-title":"Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection","volume":"204","author":"Zhang","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/jvh.12699","article-title":"Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection","volume":"24","author":"Romani","year":"2017","journal-title":"J Viral Hepat"},{"key":"B32","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.3390\/vaccines6010006","article-title":"Interaction between hepatitis B virus and toll-like receptors: current status and potential therapeutic use for chronic hepatitis B","volume":"6","author":"Ma","year":"2018","journal-title":"Vaccines"},{"key":"B33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1053\/j.gastro.2012.03.041","article-title":"Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells","volume":"143","author":"Sandalova","year":"2012","journal-title":"Gastroenterology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/hep.28282","article-title":"Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B","volume":"63","author":"Yoshio","year":"2016","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1668","article-title":"Regulation of immune responses by L-arginine metabolism","volume":"5","author":"Bronte","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1440-1746.2008.05717.x","article-title":"Site-specific cleavage of HCV genomic RNA and its cloned core and NS5B genes by DNAzyme","volume":"24","author":"Kumar","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1128\/JVI.79.6.3322-3328.2005","article-title":"Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection","volume":"79","author":"Franzese","year":"2005","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/hep.20649","article-title":"Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection","volume":"41","author":"Stoop","year":"2005","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.4049\/jimmunol.177.1.739","article-title":"Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B","volume":"177","author":"Xu","year":"2006","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0151717","DOI":"10.1371\/journal.pone.0151717","article-title":"Characterization of the treg response in the hepatitis B virus hydrodynamic injection mouse model","volume":"11","author":"Dietze","year":"2016","journal-title":"PLoS ONE"},{"key":"B41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/hep.29155","article-title":"Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models","volume":"66","author":"Kosinska","year":"2017","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.4049\/jimmunol.1501362","article-title":"Polarization of monocytic myeloid-derived suppressor cells by hepatitis B surface antigen is mediated via ERK\/IL-6\/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection","volume":"195","author":"Fang","year":"2015","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nm.3856","article-title":"Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells","volume":"21","author":"Pallett","year":"2015","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e1007690","DOI":"10.1371\/journal.ppat.1007690","article-title":"Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection","volume":"15","author":"Yang","year":"2019","journal-title":"PLoS Pathog"},{"key":"B45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1073\/pnas.0913498107","article-title":"Immune effectors required for hepatitis B virus clearance","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1004032","DOI":"10.1371\/journal.ppat.1004032","article-title":"Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages","volume":"10","author":"Bility","year":"2014","journal-title":"PLoS Pathog"},{"key":"B48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coviro.2018.04.003","article-title":"Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination","volume":"30","author":"Dembek","year":"2018","journal-title":"Curr Opin Virol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/hep.510250631","article-title":"Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer","volume":"25","author":"Lau","year":"1997","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/TP.0b013e31818bfc85","article-title":"Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients","volume":"87","author":"Schumann","year":"2009","journal-title":"Transplantation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.bpg.2017.05.004","article-title":"New treatments to reach functional cure: rationale and challenges for emerging immune-based therapies","volume":"31","author":"Gehring","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/17460441.2018.1473372","article-title":"Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections","volume":"13","author":"Du","year":"2018","journal-title":"Expert Opin Drug Discov"},{"key":"B53","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1021\/acsinfecdis.8b00297","article-title":"Toward curative immunomodulation strategies for chronic hepatitis B virus infection","volume":"5","author":"Zhu","year":"2019","journal-title":"ACS Infect Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.antiviral.2015.07.006","article-title":"Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure","volume":"121","author":"Chang","year":"2015","journal-title":"Antiviral Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.antiviral.2015.11.001","article-title":"Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection","volume":"125","author":"Meng","year":"2016","journal-title":"Antiviral Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"7269","DOI":"10.1128\/JVI.79.11.7269-7272.2005","article-title":"Toll-like receptor signaling inhibits hepatitis B virus replication in vivo","volume":"79","author":"Isogawa","year":"2005","journal-title":"J Virol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1517\/17460441.2012.689281","article-title":"Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections","volume":"7","author":"Zhang","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"B58","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/cmi.2014.112","article-title":"Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses","volume":"12","author":"Ma","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/hep.21897","article-title":"Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice","volume":"46","author":"Wu","year":"2007","journal-title":"Hepatology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2567.2009.03179.x","article-title":"Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific","volume":"129","author":"Wu","year":"2010","journal-title":"Immunology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.4049\/jimmunol.1501997","article-title":"TLR-mediated innate production of IFN-gamma by CD8+ T cells is independent of glycolysis","volume":"196","author":"Salerno","year":"2016","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3389\/fimmu.2019.02191","article-title":"Toll-like receptor 7 activation enhances CD8+ T cell effector functions by promoting cellular glycolysis","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"714","DOI":"10.4049\/jimmunol.1801026","article-title":"Costimulation through TLR2 drives polyfunctional CD8(+) T cell responses","volume":"202","author":"Salerno","year":"2019","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.4049\/jimmunol.1900065","article-title":"TLR2 stimulation increases cellular metabolism in CD8(+) T cells and thereby enhances CD8(+) T cell activation, function, and antiviral activity","volume":"203","author":"Zhang","year":"2019","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41423-019-0255-8","article-title":"Activation of the TLR signaling pathway in CD8+ T cells counteracts liver endothelial cell-induced T cell tolerance","volume":"16","author":"Zhang","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J Hepatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1508\u201317","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology."},{"key":"B68","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jhep.2017.12.007","article-title":"Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism","volume":"68","author":"Niu","year":"2018","journal-title":"J Hepatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e0161313","DOI":"10.1371\/journal.pone.0161313","article-title":"Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the woodchuck model of chronic hepatitis B","volume":"11","author":"Korolowicz","year":"2016","journal-title":"PLoS ONE"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e0169631","DOI":"10.1371\/journal.pone.0169631","article-title":"Antiviral efficacy and host immune response induction during sequential treatment with SB 9200 followed by entecavir in woodchucks","volume":"12","author":"Suresh","year":"2017","journal-title":"PLoS ONE"},{"key":"B71","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/febs.13563","article-title":"The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly","volume":"283","author":"Dansako","year":"2016","journal-title":"FEBS J"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1099\/jgv.0.000647","article-title":"Inhibition of hepatitis B virus replication by activation of the cGAS-STING pathway","volume":"97","author":"He","year":"2016","journal-title":"J Gen Virol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.04321-14","article-title":"STING agonists induce an innate antiviral immune response against hepatitis B virus","volume":"59","author":"Guo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B74","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hep.28685","article-title":"Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection","volume":"64","author":"Thomsen","year":"2016","journal-title":"Hepatology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e00771","DOI":"10.1128\/AAC.00771-17","article-title":"Activation of stimulator of interferon genes in hepatocytes suppresses the replication of hepatitis B virus","volume":"61","author":"Guo","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e0169701","DOI":"10.1371\/journal.pone.0169701","article-title":"MITA\/STING and its alternative splicing isoform MRP restrict hepatitis B virus replication","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS ONE"},{"key":"B77","doi-asserted-by":"publisher","first-page":"8321","DOI":"10.1073\/pnas.0408223102","article-title":"Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo","volume":"102","author":"Suspene","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e02190","DOI":"10.1128\/JVI.02190-17","article-title":"Asymmetric modification of hepatitis B virus (HBV) genomes by an endogenous cytidine deaminase inside HBV cores informs a model of reverse transcription","volume":"92","author":"Nair","year":"2018","journal-title":"J Virol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"13459","DOI":"10.1074\/jbc.M116.760637","article-title":"Heat shock proteins stimulate APOBEC-3-mediated cytidine deamination in the hepatitis B virus","volume":"292","author":"Chen","year":"2017","journal-title":"J Biol Chem"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.4049\/jimmunol.1203449","article-title":"IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier","volume":"191","author":"Zeng","year":"2013","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/hep.29239","article-title":"Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice","volume":"66","author":"Bian","year":"2017","journal-title":"Hepatology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","article-title":"The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection","volume":"191","author":"Maini","year":"2000","journal-title":"J Exp Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/hep.510300208","article-title":"A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T cell vaccine study group","volume":"30","author":"Heathcote","year":"1999","journal-title":"Hepatology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.vaccine.2015.03.079","article-title":"Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection","volume":"33","author":"Li","year":"2015","journal-title":"Vaccine"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.vaccine.2012.12.074","article-title":"A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice","volume":"31","author":"Buchmann","year":"2013","journal-title":"Vaccine"},{"key":"B87","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","article-title":"Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1080\/21645515.2017.1319021","article-title":"Antibody-mediated immunotherapy against chronic hepatitis B virus infection","volume":"13","author":"Gao","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B89","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/13543784.16.6.787","article-title":"Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model","volume":"16","author":"Lu","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"B90","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1566523214666140509102644","article-title":"Advances and challenges in the development of therapeutic DNA vaccines against hepatitis B virus infection","volume":"14","author":"Cova","year":"2014","journal-title":"Curr Gene Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00430-014-0379-5","article-title":"Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck","volume":"204","author":"Kosinska","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.antiviral.2015.10.009","article-title":"Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the \u201cmagic bullet\u201d to kill cccDNA","volume":"123","author":"Zhang","year":"2015","journal-title":"Antiviral Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/14712598.2017.1265940","article-title":"Present and future DNA vaccines for chronic hepatitis B treatment","volume":"17","author":"Cova","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"B94","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1073\/pnas.92.12.5307","article-title":"DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans","volume":"92","author":"Michel","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"B95","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1128\/JVI.69.10.5929-5934.1995","article-title":"Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice","volume":"69","author":"Schirmbeck","year":"1995","journal-title":"J Virol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/hep.510280126","article-title":"Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mice","volume":"28","author":"Geissler","year":"1998","journal-title":"Hepatology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1128\/JVI.01613-07","article-title":"Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model","volume":"82","author":"Lu","year":"2008","journal-title":"J Virol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e1003391","DOI":"10.1371\/journal.ppat.1003391","article-title":"Combination of DNA prime\u2013adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model","volume":"9","author":"Kosinska","year":"2013","journal-title":"PLoS Pathog"},{"key":"B99","doi-asserted-by":"publisher","first-page":"9297","DOI":"10.1128\/JVI.00506-12","article-title":"DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model","volume":"86","author":"Kosinska","year":"2012","journal-title":"J Virol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1016\/j.vaccine.2018.05.061","article-title":"The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens","volume":"36","author":"Chuai","year":"2018","journal-title":"Vaccine"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e01586","DOI":"10.1128\/JVI.01586-18","article-title":"A highly attenuated vesicular stomatitis virus-based vaccine platform controls hepatitis B virus replication in mouse models of hepatitis B","volume":"93","author":"Moshkani","year":"2019","journal-title":"J Virol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jcyt.2017.07.011","article-title":"T-cell therapy for chronic viral hepatitis","volume":"19","author":"Bertoletti","year":"2017","journal-title":"Cytotherapy"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e1003490","DOI":"10.1371\/journal.ppat.1003490","article-title":"CD40 activation rescues antiviral CD8(+) T cells from PD-1-mediated exhaustion","volume":"9","author":"Isogawa","year":"2013","journal-title":"PLoS Pathog"},{"key":"B105","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1365-2893.2010.01320.x","article-title":"Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B","volume":"18","author":"Akbar","year":"2011","journal-title":"J Viral Hepat"},{"key":"B106","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2012.07.011","article-title":"Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus","volume":"96","author":"Akbar","year":"2012","journal-title":"Antiviral Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.humimm.2014.09.021","article-title":"The dual-functional capability of cytokine-induced killer cells and application in tumor immunology","volume":"76","author":"Zhang","year":"2015","journal-title":"Hum Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy","volume":"8","author":"Gao","year":"2017","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jcyt.2016.05.015","article-title":"Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell \/dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: a systematic review and meta-analysis","volume":"18","author":"Mu","year":"2016","journal-title":"Cytotherapy"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00262-004-0554-4","article-title":"Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma","volume":"53","author":"Schmidt","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jhep.2019.02.016","article-title":"OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection","volume":"70","author":"Jacobi","year":"2019","journal-title":"J Hepatol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"15001","DOI":"10.1073\/pnas.1312772110","article-title":"Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)","volume":"110","author":"Fuller","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J Hepatol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clim.2011.06.007","article-title":"Th3 immune responses in the progression of leprosy via molecular cross-talks of TGF-beta, CTLA-4 and Cbl-b","volume":"141","author":"Kumar","year":"2011","journal-title":"Clin Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/eji.201141852","article-title":"Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B","volume":"42","author":"Wu","year":"2012","journal-title":"Eur J Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/jvh.12255","article-title":"Adaptive response in hepatitis B virus infection","volume":"21","author":"Loggi","year":"2014","journal-title":"J Viral Hepat"},{"key":"B117","doi-asserted-by":"publisher","first-page":"a021428","DOI":"10.1101\/cshperspect.a021428","article-title":"Immune response in hepatitis B virus infection","volume":"5","author":"Tan","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"B119","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J Hepatol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B121","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1172\/JCI93024","article-title":"Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection","volume":"127","author":"Kah","year":"2017","journal-title":"J Clin Invest"},{"key":"B123","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jcyt.2018.02.002","article-title":"HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice","volume":"20","author":"Kruse","year":"2018","journal-title":"Cytotherapy"},{"key":"B124","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.ymthe.2019.02.001","article-title":"Evaluation of a fully human, hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model","volume":"27","author":"Festag","year":"2019","journal-title":"Mol Ther"},{"key":"B125","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1016\/S0168-8278(15)30005-2","article-title":"Engineered Hbv-specific T cells: disentangling antiviral from killing capacity","volume":"62","author":"Koh","year":"2015","journal-title":"J Hepatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","article-title":"Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study","volume":"32","author":"Gaggar","year":"2014","journal-title":"Vaccine"},{"key":"B127","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology."},{"key":"B129","doi-asserted-by":"publisher","first-page":"S302","DOI":"10.1016\/S0168-8278(11)60753-8","article-title":"Treatment of chronic hepatitis B infection with Dv-601, a therapeutic vaccine","volume":"54","author":"Spellman","year":"2011","journal-title":"J Hepatol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e0201236","DOI":"10.1371\/journal.pone.0201236","article-title":"Treatment of chronic hepatitis B naive patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)","volume":"13","author":"Al Mahtab","year":"2018"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S0618-8278(19)30090-8","article-title":"PS-078-A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection","volume":"70","author":"Lim","year":"2019","journal-title":"J Hepatol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/hep.20408","article-title":"Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers","volume":"40","author":"Mancini-Bourgine","year":"2004","journal-title":"Hepatology"},{"key":"B133","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1016\/j.vaccine.2005.08.013","article-title":"Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers","volume":"24","author":"Mancini-Bourgine","year":"2006","journal-title":"Vaccine"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/S0618-8278(19)30944-2","article-title":"FRI-199-First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis","volume":"70","author":"Ibironke","year":"2019","journal-title":"J Hepatol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/jvh.12942","article-title":"Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment","volume":"25","author":"Agarwal","year":"2018","journal-title":"J Viral Hepat"},{"key":"B136","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J Hepatol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/S0618-8278(19)30943-0","article-title":"FRI-198-A Phase, double-blind, randomized, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral JNJ-64794964, a toll-like receptor-7 agonist, in healthy adults","volume":"70","author":"Gane","year":"2019","journal-title":"J Hepatol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis b: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijid.2006.09.010","article-title":"Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens","volume":"11","author":"Betancourt","year":"2007","journal-title":"Int J Infect Dis"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.vaccine.2006.11.019","article-title":"Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients","volume":"25","author":"Yao","year":"2007","journal-title":"Vaccine"},{"key":"B141","doi-asserted-by":"publisher","first-page":"e2565","DOI":"10.1371\/annotation\/8b913538-74f4-4560-b700-0936a8e35847","article-title":"A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients","volume":"3","author":"Xu","year":"2008","journal-title":"PLoS ONE"},{"key":"B142","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"59","author":"Xu","year":"2013","journal-title":"J Hepatol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1080\/21645515.2017.1335840","article-title":"Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients","volume":"13","author":"Zhou","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/sj.gt.3302751","article-title":"Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study","volume":"13","author":"Yang","year":"2006","journal-title":"Gene Ther"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","author":"Zoulim","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B147","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J Hepatol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with Nucleos(T)Ide analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e0144383","DOI":"10.1371\/journal.pone.0144383","article-title":"AIC649 induces a Bi-Phasic treatment response in the woodchuck model of chronic hepatitis B","volume":"10","author":"Paulsen","year":"2015","journal-title":"PLoS ONE"},{"key":"B150","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jmv.24306","article-title":"The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation","volume":"88","author":"Sun","year":"2016","journal-title":"J Med Virol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/sji.12097","article-title":"A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B","volume":"78","author":"Ma","year":"2013","journal-title":"Scand J Immunol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clim.2009.03.001","article-title":"Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection","volume":"132","author":"Shi","year":"2009","journal-title":"Clin Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","article-title":"HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to Nucleos(t)ide analog: new switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3389\/fimmu.2017.00621","article-title":"Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients","volume":"8","author":"Phillips","year":"2017","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.cld.2019.04.005","article-title":"HBV\/HDV coinfection: a challenge for therapeutics","volume":"23","author":"Koh","year":"2019","journal-title":"Clin Liver Dis"},{"key":"B158","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.4049\/jimmunol.166.2.1405","article-title":"Targeting murine immune responses to selected T cell- or antibody-defined determinants of the hepatitis B surface antigen by plasmid DNA vaccines encoding chimeric antigen","volume":"166","author":"Schirmbeck","year":"2001","journal-title":"J Immunol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"10421","DOI":"10.1128\/JVI.00996-14","article-title":"Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model","volume":"88","author":"Wu","year":"2014","journal-title":"J Virol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00281-017-0641-1","article-title":"Tolerance and immunity to pathogens in early life: insights from HBV infection","volume":"39","author":"Hong","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.jhep.2016.01.040","article-title":"Effector T cell function rather than survival determines extent and duration of hepatitis in mice","volume":"64","author":"Vo","year":"2016","journal-title":"J Hepatol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.ymthe.2017.06.018","article-title":"TLR9-mediated conditioning of liver environment is essential for successful intrahepatic immunotherapy and effective memory recall","volume":"25","author":"Cebula","year":"2017","journal-title":"Mol Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.4049\/jimmunol.1700921","article-title":"Local stimulation of liver sinusoidal endothelial cells with a NOD1 agonist activates T cells and suppresses hepatitis B virus replication in mice","volume":"200","author":"Huang","year":"2018","journal-title":"J Immunol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.it.2012.04.006","article-title":"Tertiary lymphoid organs in infection and autoimmunity","volume":"33","author":"Neyt","year":"2012","journal-title":"Trends Immunol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/ni.2573","article-title":"Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection","volume":"14","author":"Huang","year":"2013","journal-title":"Nat Immunol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.jhep.2017.12.008","article-title":"Anti-HBV response to toll-like receptor 7agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells","volume":"68","author":"Li","year":"2018","journal-title":"J Hepatol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1084\/jem.20121172","article-title":"Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion","volume":"210","author":"Peppa","year":"2013","journal-title":"J Exp Med"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/hep.26115","article-title":"Natural killer cells in liver disease","volume":"57","author":"Tian","year":"2013","journal-title":"Hepatology"},{"key":"B171","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","article-title":"Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B","volume":"58","author":"Micco","year":"2013","journal-title":"J Hepatol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/infdis\/jiv180","article-title":"Natural killer cell characteristics in patients with chronic Hepatitis B Virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with pegylated interferon Alfa-2a and Adefovir","volume":"212","author":"Stelma","year":"2015","journal-title":"J Infect Dis"},{"key":"B173","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2012.10.039","article-title":"Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice","volume":"144","author":"Li","year":"2013","journal-title":"Gastroenterology"},{"key":"B174","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J Clin Invest"},{"key":"B175","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J Clin Invest"},{"key":"B176","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jhep.2019.07.015","article-title":"Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B","volume":"72","author":"Le Bert","year":"2019","journal-title":"J Hepatol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3389\/fimmu.2019.02308","article-title":"Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response","volume":"10","author":"Ma","year":"2019","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3389\/fgene.2019.00696","article-title":"Host genetic determinants of hepatitis B virus infection","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Genet"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/hep.30497","article-title":"A functional variant in ubiquitin conjugating enzyme E2 L3 contributes to hepatitis B virus infection and maintains covalently closed circular DNA stability by inducing degradation of apolipoprotein B mRNA editing enzyme catalytic subunit 3A","volume":"69","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/infdis\/jix683","article-title":"Differentially expressed intrahepatic genes contribute to control of hepatitis B virus replication in the inactive carrier phase","volume":"217","author":"Liu","year":"2018","journal-title":"J Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.03127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T23:37:12Z","timestamp":1581032232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.03127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":180,"alternative-id":["10.3389\/fimmu.2019.03127"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.03127","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"article-number":"3127"}}